Icatibant is categorized as Bradykinin B2 receptor antagonist peptide mimetic; its regulatory category in this atlas is FDA-approved peptide drug or regulated peptide/hormone medication.
Fda LabelPEPTIDE DOSSIER
Icatibant
Icatibant is classified as Bradykinin B2 receptor antagonist peptide mimetic. This profile separates what is known from source-linked evidence, what remains uncertain, safety considerations, and the US regulatory context.
Firazyr
Executive Summary
What is it?
Icatibant is a profile in the atlas because people search for it as a peptide, peptide medicine, peptide-like hormone, supplement ingredient, cosmetic peptide, or nearby comparison item. The key question is not just what it is called, but whether a specific product has reliable evidence, clear safety information, and a verified regulatory pathway.
What is it used or studied for?
Icatibant is commonly searched in connection with Hereditary angioedema attack treatment depending on product label. Some uses may be approved for specific products, while others may only be studied, speculative, cosmetic, supplement-related, or unsupported.
How it interacts with the body
In simple terms, Icatibant is discussed through Bradykinin B2 receptor antagonism. That means the profile focuses on the body signal, receptor, or pathway it is believed or known to affect, while separating proven labeled uses from research-only claims.
What we know
- - Icatibant is categorized as Bradykinin B2 receptor antagonist peptide mimetic.
- - Icatibant currently has evidence grade A in this atlas.
- - Regulatory category: FDA-approved peptide drug or regulated peptide/hormone medication.
What remains uncertain
- - Product-specific legality, quality, and labeling can vary by jurisdiction and supplier.
- - Long-term safety and real-world adverse-event patterns may be incomplete outside approved product contexts.
- - Claims not tied to FDA labeling or human trials should be treated cautiously.
Non-technical takeaway
Icatibant should be read through three filters: what the evidence says, what the regulatory status actually means, and what safety uncertainties remain.
People usually search Icatibant to understand potential uses, how it works in the body, whether it is approved, and what safety concerns or evidence gaps matter.
Key safety considerations
Safety context for Icatibant should be interpreted through product-specific labels or the limits of available research. Non-approved products should not be treated as safe for human use.
Chemical and Scientific Profile
- Peptide type
- Bradykinin B2 receptor antagonist peptide mimetic
- Sequence
- Unknown
- Formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- Unknown
- Targets
- bradykinin B2 receptor
- Routes studied
- subcutaneous
Molecular visualization placeholder
Mechanism of Action
Explain like I’m new
Icatibant is discussed through the pathway: Bradykinin B2 receptor antagonism. The plain-language interpretation should stay anchored to verified evidence and labeled uses.
Advanced scientific view
Advanced view: Bradykinin B2 receptor antagonism. Receptor/pathway details require claim-level citations before being treated as clinically meaningful.
Bradykinin B2 receptor antagonism
Benefits and Claims
Supported
Preclinical Only
Icatibant should be interpreted through source-linked evidence, not marketing claims or protocol claims.
Fda LabelUnsupported / Safety Claim
Icatibant has product-specific label warnings and should only be used under licensed clinician supervision according to the prescribing label.
Fda LabelEvidence Dashboard
A
Evidence grade
FDA label and human clinical evidence for labeled uses
Human data
not the primary evidence basis for labeled uses
Animal data
high for labeled uses
Citation quality
source search placeholder
Research tracker for Icatibant
- Population
- Not yet curated from a specific trial.
- Intervention
- Icatibant
- Comparator
- Not yet curated.
- Outcomes
- Research outcomes require manual source review.
- Limitations
- This study card is a seed-level summary and should be replaced by full PICO extraction during editorial review.
- Funding/conflict
- Funding and conflict notes require editorial extraction from the full source.
Dosing and Administration Guardrails
Use only according to the approved prescribing information and a licensed clinician. This site does not provide dosing instructions.
This site does not provide personalized protocols, DIY preparation, injection, reconstitution, or self-administration instructions.
Safety Section
Common side effects
- - not well characterized in this seed
Serious warnings
- - unknown long-term safety or product-specific warning gaps
Contraindications
- - not fully characterized; consult product-specific labeling or clinician
Interactions
- - not fully characterized
Regulatory and Sport Status
Comparisons
Compare evidence, regulatory status, route, and safety context before treating two compounds as similar.
FAQs
Is Icatibant FDA-approved?
Icatibant appears in an FDA-regulated product context for specific labeled uses. Approval applies to the specific product and indication, not every market product using the same ingredient name.
What is the main evidence caveat for Icatibant?
Icatibant is categorized as FDA-approved peptide drug or regulated peptide/hormone medication. Evidence strength depends on whether a claim comes from FDA labeling, human trials, animal studies, in vitro work, or unsupported marketing.
Does this page provide dosing instructions for Icatibant?
No. For approved products, this site points users back to the prescribing label and a licensed clinician.